Go Back This article was viewed 78 times

Review Article


Immune profile of tumor and chemotherapy

Bakulesh Khamar
Department of R and D, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India
Corresponding Author:

Bakulesh Khamar

Department of R and D, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India
E-mail: bmk@cadilapharma.co.in

Corresponding Author:

Bakulesh Khamar

Department of R and D, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India
E-mail: bmk@cadilapharma.co.in

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20183228

ABSTRACT


Chemotherapy works through its activity on cancer cells. It generally suppresses cell-mediated immunity but also improves cell-mediated immune response by making tumor cells vulnerable to killing by cell-mediated immune responses as well as through its action on immunostimulant and immunosuppressive cells. Outcome of chemotherapy seems to be dependent on baseline tumor-infiltrating immune cells (TII) as well as changes in TII following chemotherapy in varieties of tumors. Evaluation of density and site of two TII is done in immunoscore. It is a better marker than evaluation of a single TII. Evaluation of TII can have prognostic and predictive value and can help in the better stratifying prognostic value of current classification
Keywords: CD4 T cells, CD8 T cells, Cell-mediated immune response, Chemotherapy, Macrophages, Natural killer cells, Predictive biomarker, Prognostic biomarker, T lymphocytes, Treg cells

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.